Seno Medical Instruments, Inc.
RELATED CONTENT
July 26, 2022 — Seno Medical’s Imagio Breast Imaging System, a revolutionary new modality in breast imaging, has ...
July 26, 2022 
April 23, 2021 — The U.S. Food and Drug Administration (FDA) has approved Seno Medical's Imagio P200003 Breast Imaging ...
April 23, 2021 
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional opto-acoustic (OA/US) features provide a non-invasive approach to helping distinguish breast cancer molecular subtypes. The data were presented at the Radiological Society of North America (RSNA) 2018 annual meeting, Nov. 25-30 in Chicago, and the abstract was featured as one of three High Impact Clinical Trials selected for this special session.
December 20, 2018 
May 8, 2018 — The American Journal of Roentgenology recently published findings on statistical methods for downgrading ...
May 08, 2018 
Seno Medical Instruments Inc. (Seno Medical) recently reported data from their clinical study demonstrating that its Imagio opto-acoustic (OA) breast imaging system achieved significant differentiation among prognostic subtypes of breast cancer (PSBC). These prognostic subtypes provide important information about the genes that each patient's cancer expresses. The data were presented during a poster presentation at the San Antonio Breast Cancer Symposium, Dec. 5-9 in San Antonio, Texas.
January 02, 2018 
Seno Medical Instruments Inc. recently announced that is Imagio opto-acoustic (OA/US) breast imaging system results correlate with the histopathological findings of benign and malignant breast masses. These data were highlighted during an oral presentation at the American Roentgen Ray Society (ARRA) Annual Meeting, May 1-5 in New Orleans.
May 16, 2017 Seno Medical Instruments, Inc. announced results from two analyses of the company's European MAESTRO post-market surveillance study. The two analyses were presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) in San Antonio.
January 17, 2017 
Seno Medical Instruments Inc. announced results of its pilot study portion of the PIONEER pivotal study at the 2015 Radiological Society of North America (RSNA) annual meeting.
December 22, 2015 
Seno Medical Instruments Inc. (Seno) announced it has completed the final phase of the company's U.S.-based PIONEER pivotal study of the Imagio breast imaging system. The system utilizes optoacoustic technology as a new tool to improve the process of diagnosing breast cancer.
September 29, 2015 
Seno Medical Instruments Inc. announced that the use of the Seno Imagio breast imaging system and the associated predictive model appear to have the potential to significantly improve physicians' ability to accurately rule out breast cancer compared to traditional ultrasound alone.
November 11, 2014